Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29844344 | 1.00 | HSD17B10 (0.48) | HSD17B10ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL836980 | 0.80 | IDO1 (0.47) | KMT2A | |
| SCHEMBL3119367 | 0.79 | ALDH1A1 (0.59) | ALDH1A1GAATTRLMNA | |
| SCHEMBL25801611 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2GAACA1CA2 | |
| SCHEMBL29844275 | 0.79 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2GAACA1CA2 | |
| SCHEMBL7896877 | 0.78 | ALDH1A1 (0.56) | HSD17B10ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3777114 | 0.77 | MEN1 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL29844260 | 0.77 | MEN1 (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL921998 | 0.76 | GAA (0.68) | HSD17B10ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3616256 | 0.76 | ALDH1A1 (0.53) | HSD17B10ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | HSD17B10 2079/4885ALDH1A1 134/4885MEN1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.